Radiopharm Theranostics Files 6-K

TL;DR

Radiopharm Theranostics (RPT) filed a 6-K on Jan 10, 2025, confirming its Australian base and industry.

AI Summary

Radiopharm Theranostics Limited filed a Form 6-K on January 10, 2025, reporting information for the month of January 2025. The company is incorporated in Australia and its principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053. Radiopharm Theranostics Limited is classified under Pharmaceutical Preparations.

Why It Matters

This filing provides routine updates for foreign private issuers, informing investors about the company's operational status and location.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

• Radiopharm Theranostics Limited (company) — Registrant
• 001-41621 (company) — SEC File Number
• January 2025 (date) — Reporting Period
• Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (location) — Principal Executive Office

FAQ

Key Financial Figures

• $8m — eus increases shareholding in RAD with A$8m placement” A copy of the Public

Filing Documents

• ea0227336-6k_radio.htm (6-K) — 12KB
• ea022733601ex99-1_radio.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 10KB
• 0001213900-25-002340.txt ( ) — 40KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on January 10, 2025 titled: - “Lantheus increases shareholding in RAD with A$8m placement” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Lantheus increases shareholding in RAD with A$8m placement 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: January 10, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR